-
公开(公告)号:US20230381508A1
公开(公告)日:2023-11-30
申请号:US18201881
申请日:2023-05-25
发明人: Kip Ludwig , Justin Williams , Kevin Cheng , Nishant Verma
CPC分类号: A61N1/36025 , A61N1/0456 , A61N1/36034
摘要: Administration of low frequency electrical stimulation of the cranial nerves delivered during sleep increases the presence and function of aquaporin-4 (AQP4) channels in the astrocytic endfeet surrounding descending arterioles in the brain. This underlying low frequency stimulation pattern is overlaid with temporally patterned ‘bursts’ of higher frequency stimulation to pulse the underlying artery to drive cerebrospinal fluid (CSF) penetration into the parenchyma. This also serves to create more movement in general within the parenchymal extracellular space to increase the probability of waste biomolecules to interact with sites for active transport out of the brain. During the period of sleep, these two layered patterns will be periodically replaced with multiple continuous periods of stimulation at gamma frequency to promote a more phagocytic phenotype in glial cells to help break down waste biomolecules and misfolded proteins for subsequent clearance. Administration of electrical stimulation can be selectively modified to adjust CSF clearance, for example, to quickly clear drug concentrations in the brain during an overdose.
-
公开(公告)号:US20240307681A1
公开(公告)日:2024-09-19
申请号:US18672957
申请日:2024-05-23
发明人: Justin Williams , Kip Ludwig , Erika Ross
CPC分类号: A61N1/056 , A61N1/0456 , A61N1/0476 , A61N1/0484 , A61N1/0492 , A61N1/0536 , A61N1/0551 , A61N1/36025 , A61N1/36034 , A61N1/36053 , A61N1/36067 , A61N1/36082 , A61N1/36103 , A61N1/36132 , A61N1/36146 , A61N1/36175 , A61N1/37516
摘要: The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the present invention provides materials and methods for modulating glymphatic clearance (e.g., enhancing glymphatic clearance) of pathogenic proteins.
-
公开(公告)号:US11426577B2
公开(公告)日:2022-08-30
申请号:US16326824
申请日:2017-08-25
发明人: Justin Williams , Kip Ludwig , Erika Ross
摘要: The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the present invention provides materials and methods for modulating glymphatic clearance (e.g., enhancing glymphatic clearance) of pathogenic proteins.
-
4.
公开(公告)号:US20230381509A1
公开(公告)日:2023-11-30
申请号:US18201887
申请日:2023-05-25
发明人: Kip Ludwig , Nishant Verma , Justin Williams
IPC分类号: A61N1/36
CPC分类号: A61N1/36025 , A61N1/36031 , A61N1/36034
摘要: Real-time sensing of cerebrospinal fluid (CSF) clearance can be used to optimize electrode target engagement of the peripheral cranial nerves and detect associated changes within the connected nerve truck and brain. This CSF clearance data may be used in “open loop” systems to inform operator-controlled programming or sent directly to the stimulator itself to titrate programming “closed loop” on the device.
-
公开(公告)号:US20190201684A1
公开(公告)日:2019-07-04
申请号:US16326824
申请日:2017-08-25
发明人: Justin Williams , Kip Ludwig , Erika Ross
CPC分类号: A61N1/056 , A61N1/0456 , A61N1/0476 , A61N1/0484 , A61N1/0492 , A61N1/0536 , A61N1/0551 , A61N1/36025 , A61N1/36034 , A61N1/36053 , A61N1/36067 , A61N1/36082 , A61N1/36103 , A61N1/36132 , A61N1/36146 , A61N1/36175 , A61N1/37516
摘要: The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the present invention provides materials and methods for modulating glymphatic clearance (e.g., enhancing glymphatic clearance) of pathogenic proteins.
-
公开(公告)号:US12076554B2
公开(公告)日:2024-09-03
申请号:US17854078
申请日:2022-06-30
发明人: Kip Ludwig , Justin Williams , Angela Williams , Samuel Poore
CPC分类号: A61N1/0548 , A61N1/0432 , A61N1/36025
摘要: Electrical stimulation of specific facial and lingual nerves creates a more sustained pulsatility activity compared to stimulation of other cranial nerves. Pulsatility of arteries has intrinsic time constraints related to the time for vasodilation/constriction and time to return to baseline (TBL) after electrical stimulation which may affect the pulsatility response. Control of temporal patterning and the stimulation waveform maximizes the physiological response to cerebral pulsatility and its resulting effects on cerebral spinal fluid penetration into the brain parenchyma for a multitude of therapeutic uses including clearing misfolded proteins and/or administered pharmacological agents, diluting endogenous neurochemical concentrations within the brain, and reducing non-synaptic coupling.
-
公开(公告)号:US12005251B2
公开(公告)日:2024-06-11
申请号:US17884784
申请日:2022-08-10
发明人: Justin Williams , Kip Ludwig , Erika Ross
CPC分类号: A61N1/056 , A61N1/0456 , A61N1/0476 , A61N1/0484 , A61N1/0492 , A61N1/0536 , A61N1/0551 , A61N1/36025 , A61N1/36034 , A61N1/36053 , A61N1/36067 , A61N1/36082 , A61N1/36103 , A61N1/36132 , A61N1/36146 , A61N1/36175 , A61N1/37516
摘要: The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the present invention provides materials and methods for modulating glymphatic clearance (e.g., enhancing glymphatic clearance) of pathogenic proteins.
-
公开(公告)号:US20220379108A1
公开(公告)日:2022-12-01
申请号:US17884784
申请日:2022-08-10
发明人: Justin Williams , Kip Ludwig , Erika Ross
摘要: The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the present invention provides materials and methods for modulating glymphatic clearance (e.g., enhancing glymphatic clearance) of pathogenic proteins.
-
-
-
-
-
-
-